News and Trends 29 Sep 2022 Umeå Biotech Incubator launches international coaching program The Umeå Biotech Incubator (UBI) in Sweden specializes in developing life science business ideas. Now it is launching an international incubator program. “If you strive to be one of the world’s best incubators you must have the whole world as your marketplace,” said Jennie Ekbeck, CEO of Umeå Biotech Incubator. Umeå Biotech Incubator was founded […] September 29, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2022 Mucocort signs deal for pain-relieving mouth ulcer treatment Mucocort AB is a Swedish company that has developed a unique self-absorbing pain relief patch for people suffering from recurrent mouth ulcers – aphthous stomatitis. The company has signed a production agreement with medical technology company Aurena Laboratories AB, which also becomes a stakeholder in Mucocort. Aphthous stomatitis is a common disorder. Sixty percent of […] September 26, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2022 Knockback for drug to treat patients with relapsed or refractory multiple myeloma A Swedish biotech company says it believes its treatment could be the ‘canary in the coalmine’ despite a knockback. The Oncologic Drugs Advisory Committee (ODAC) has said it does not consider the treatment for patients with relapsed or refractory multiple myeloma (RRMM) favorable in a benefit-risk profile. Oncopeptides AB has been trialing Pepaxto in the […] September 23, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2022Beyond Biotech podcast 15: Cullinan Oncology, Pleco Therapeutics, TikoMed This week’s podcast has three guests. In honor of World Cancer Research Day on September 24, we have an overview of cancer research with Nadim Ahmed, CEO of Cullinan Oncology; a chat with Ivo Timmermans, CEO of Pleco Therapeutics; and talk with Anders Kristensson, CEO of TikoMed. We also have our weekly chat with global […] September 23, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Cyxone receives approval for phase 2b rheumatoid arthritis study Swedish biotech company Cyxone has received approval from the Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and the Central Ethics Committee in Poland to start a clinical phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). “The approval is […] September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022Beyond Biotech podcast 14: Nordic Life Science NLS Days 2022 This week’s podcast is dedicated to Nordic Life Science Days, otherwise known as NLS Days. This year’s version is an in-person event from September 28-29, at the Malmömässan in Malmö, Sweden. In our preview of NLS Days, which features sessions and fireside chats, company presentations, an exhibition, and one-on-one partnering meetings, we have interviews with […] September 16, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Omnio receives funding for wound treatment Swedish company Omnio AB has shown plasminogen is a pro-inflammatory regulator of inflammation that can be used to treat chronic wounds with dysfunctional inflammation. The company, a spin off from Umeå University, said the drug could mean a global treatment revolution for wounds that never heal. Non-healing chronic wounds are a major global health problem […] September 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Oncopeptides receives grant for NK-cell engager project in multiple myeloma Oncopeptides AB has received a SEK 5 million ($465,000) research grant from Sweden’s Innovation Agency. The Swedish biotech company, which focuses on R&D of therapies for difficult-to-treat hematological diseases, will use the funds to develop a preclinical proof of concept (PoC) for a novel synthetic small polypeptide for the treatment of multiple myeloma. The compound […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 7 Sep 2022 The biggest private biotech investments in August 2022 The healthcare-focused companies Orna Therapeutics, F2G and Sironax bagged the biggest biotech investments in August 2022, with mRNA vaccines, genomics and fermentation technology attracting big funding rounds. As many took a well-deserved vacation in the month of August 2022, the world of biotech remained busy with fundraising. Sit back and browse our lists of the […] September 7, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Alzinova announces new positive safety review for Alzheimer’s study Alzinova AB says a second external safety review has been carried out of its clinical phase 1b study. This resulted in a positive assessment to continue the study as planned. Behind the review is an independent expert group, Data and Safety Monitoring Board (DSMB), which continuously reviews the study. Based on the patients included in […] September 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 TikoMed drug inhibits infection of human cells by dengue, zika and yellow fever viruses TikoMed has announced the inclusion in bioRxiv of an in vitro study examining the ability of the company’s lead drug candidate ILB to inhibit infection of human cells by four serotypes of dengue virus (DENV1-4), two strains of zika virus (African and Asian) and yellow fever virus (vaccine strain YF17D) assessed by immunofluorescence of viral […] September 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 IRLAB’s partner Ipsen starts mesdopetam clinical studies IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson’s disease, says its partner, Ipsen, has initiated clinical studies with drug candidate mesdopetam in accordance with its development plan. These are standard clinical pharmacokinetic studies that will run in parallel to the phase IIb study with […] September 6, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email